NESS ZIONA, Israel, June 28,
2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.
(Nasdaq: BVXV), developer of M‑001, a clinical phase Universal
Influenza Vaccine candidate, announced today the appointment of Mr.
Mark Germain as Vice-Chairman of its
Board of Directors.
Based in New York, and having
served as founder, director, chairman of the board, and/or investor
in over twenty biotech companies, and with experience assisting in
arranging corporate partnerships, acquiring technology, entering
mergers and acquisitions, and executing financings, Mr. Germain is
well suited to help guide BiondVax's ongoing corporate development.
Among his current positions, Mr. Germain is a Managing Director at
The Aentib Group, a boutique merchant bank, and serves as a
director on the board of the Israeli company Pluristem Therapeutics
Inc. (Nasdaq: PSTI).
Mr. Mark Germain
commented, "I am pleased and excited to join the BiondVax board
at this important time in the development of the company. It is
about to commence a Phase 3 pivotal trial for its universal flu
vaccine, an innovative multi-strain, multi-season product with the
potential to protect against pandemic strains as well. We
have a strong shareholder base, with €20 million
additional non-dilutive funding from the European Investment Bank,
and are poised to build a successful company. I'm looking forward
to working with our CEO Ron
Babecoff, the rest of the board, and shareholders."
Dr. Ron Babecoff, BiondVax's President and CEO, remarked,
"On behalf of BiondVax's Board of Directors, I warmly welcome
Mark's appointment. I am confident that his biotech and corporate
experience and track record will contribute significantly to
BiondVax's upcoming activities."
"This year we plan to launch our universal flu vaccine's
first pivotal, clincal efficacy, Phase 3 trial, and are
constructing our mid-size commercial scale manufacturing facility.
Mark's advice and guidance, along with that of the rest of our
Board, will be valuable to BiondVax's future," continued
Babecoff.
About BiondVax
BiondVax (Nasdaq: BVXV) is an advanced clinical stage
biopharmaceutical company developing a universal flu vaccine. The
vaccine candidate, called M-001, is designed to provide
multi-season protection against current and future, seasonal and
pandemic influenza virus strains. BiondVax's proprietary technology
utilizes a unique combination of conserved and common influenza
virus peptides, activating both arms of the immune system for a
cross-protecting and long-lasting effect. In a total of 6 completed
Phase 1/2 and Phase 2 human clinical trials, covering 698
participants, the vaccine has been shown to be safe,
well-tolerated, and immunogenic. Please visit www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements involve certain risks and uncertainties reflect the
management's current views with respect to certain current and
future events and are subject to various risks, uncertainties and
assumptions that could cause the results to differ materially from
those expected by the management of BiondVax Pharmaceuticals Ltd.
risks and uncertainties include, but are not limited to, the risk
that drug development involves a lengthy and expensive process with
uncertain outcomes, the successful completion of our planned
manufacturing facility, the results of the ongoing Phase 2
trial and the pivotal Phase 3 trial, delays or obstacles in
launching and/or successfully completing our clinical trials, the
impact of the global economic environment on the Company customer
target base, the adequacy of available cash resource and the
ability to raise capital when needed. More detailed information
about the risks and uncertainties affecting the Company is
contained under the heading "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31,
2017 filed with the U.S. Securities and Exchange Commission,
or SEC, which is available on the SEC's website, www.sec.gov, and
in the Company's periodic filings with the SEC and the Tel-Aviv
Stock Exchange. We undertake no obligation to revise or
update any forward-looking statement for any reason.
Contact Details
Joshua Phillipson,
+972-8-930-2529, j.phillipson@biondvax.com
View original
content:http://www.prnewswire.com/news-releases/corporate-biotech-executive-mark-germain-joins-biondvaxs-board-of-directors-300673899.html
SOURCE Biondvax Pharmaceuticals Ltd